143 related articles for article (PubMed ID: 31022583)
1. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway.
Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT
Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma.
Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F
Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895
[TBL] [Abstract][Full Text] [Related]
3. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells.
Zhang J; Song Y; Liang Y; Zou H; Zuo P; Yan M; Jing S; Li T; Wang Y; Li D; Zhang T; Wei Z
Food Chem Toxicol; 2019 Oct; 132():110654. PubMed ID: 31265865
[TBL] [Abstract][Full Text] [Related]
4. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
[TBL] [Abstract][Full Text] [Related]
5. Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway.
Ahmed MS; El-Senduny F; Taylor J; Halaweish FT
Chem Biol Drug Des; 2017 Sep; 90(3):478-484. PubMed ID: 28171685
[TBL] [Abstract][Full Text] [Related]
6. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
7. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.
Ahmed MS; Kopel LC; Halaweish FT
ChemMedChem; 2014 Jul; 9(7):1361-7. PubMed ID: 24682977
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.
Ahmed MS; Halaweish FT
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):162-7. PubMed ID: 23368732
[TBL] [Abstract][Full Text] [Related]
10. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
11. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
14. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
Soliman AM; Alqahtani AS; Ghorab M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties.
Fang JK; Xu Z; Zhang Y; Zhang W; Liu B; Fang Y; Sun T
Anticancer Agents Med Chem; 2016; 16(12):1665-1672. PubMed ID: 27349449
[TBL] [Abstract][Full Text] [Related]
18. Triazole-estradiol analogs: A potential cancer therapeutic targeting ovarian and colorectal cancer.
Ostlund T; Alotaibi F; Kyeremateng J; Halaweish H; Kasten A; Iram S; Halaweish F
Steroids; 2022 Jan; 177():108950. PubMed ID: 34933058
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin IIb induces apoptosis and cell cycle arrest through regulating EGFR/MAPK pathway.
Liang Y; Zhang T; Ren L; Jing S; Li Z; Zuo P; Li T; Wang Y; Zhang J; Wei Z
Environ Toxicol Pharmacol; 2021 Jan; 81():103542. PubMed ID: 33161110
[TBL] [Abstract][Full Text] [Related]
20. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).
Coyne CP; Narayanan L
Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]